LB Pharmaceuticals Inc - Common Stock (LBRX)
40.15
+0.32 (0.80%)
NASDAQ · Last Trade: Oct 29th, 5:30 PM EDT
News & Press Releases
LB Pharmaceuticals Eyes 2027 Phase III Data for LB-102 in Schizophreniamarketbeat.com
LB Pharmaceuticals (NASDAQ:LBRX) outlined its clinical and commercial plans for LB-102, an investigational antipsychotic designed as a structural modification of amisulpride, during its first R&D Day in New York. The company said it expects three clinical readouts over the next three years, begi
Via MarketBeat · October 27, 2026
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumblesfool.com
Oculis advances late-stage topical therapies for diabetic and neuro-ophthalmic eye diseases in the clinical-stage biotech sector.
Via The Motley Fool · June 8, 2026
